Drug Class: Cell Cycle Inhibitors

Cell Cycle Inhibitors: CHK1/2 Inhibitors

Treatment given for recurrence occurring at any time after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

5 Prior Therapies

Cell Cycle Inhibitors: CHK1/2 Inhibitors

Treatment given for recurrence occurring at any time after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT02203513 II Prexasertib A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer

Promising activity in heavily pretreated BRCA WT patients, including those with CCNE1 alterations, but modest activity in BRCA MUT patients

BRCA WT:
ORR: 32%
PFS: 7.5 months

BRCA MUT
ORR: 11.1%

pub 2018, abs May 2020 and poster

< Return to Drug Classes

< Return to Clinical Trial Results Homepage